Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a life sciences. Over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has been involved in 1 licensing and acquisition transaction, with a primary focus on Gene Therapy (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Mega Deals
Licensing, acquisition, and partnership transactions involving Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| muscle disorder capsid | Astellas | Gene Therapy | Unknown | license | Apr 2026 |
Therapeutic areas and modalities where Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is most active based on deal history and clinical trial data.
Key indicators of Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) include Mega Deals (2 deals and trials). In terms of modality, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 3,000+ real biopharma licensing deals